Supporting evidence from diabetic nephropathy models suggests that AS-IV can enhance mitochondrial function and mitigate oxidative damage by upregulating the Nrf2-ARE/TFAM signaling pathway (Shen et al., 2023), potentially indicating mechanistic parallels in PF. This evidence concerns the gene TFAM and diabetic kidney disease.